Nasal Spray Influenza Vaccine Market Report 2026

The nasal spray influenza vaccine market size has grown rapidly in recent years. It will grow from $1.48 billion in 2025 to $1.66 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to increasing flu vaccination awareness, reliance on traditional injection-based flu vaccines, government-led influenza immunization programs, seasonal flu outbreaks, limited availability of needle-free options.

The nasal spray influenza vaccine market size is expected to see rapid growth in the next few years. It will grow to $2.68 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to growing demand for needle-free delivery systems, expansion of pediatric and geriatric immunization programs, rising investment in nasal vaccine r&d, development of advanced attenuated vaccine formulations, increasing global vaccination coverage initiatives. Major trends in the forecast period include growing adoption of needle-free vaccination methods, rising demand for pediatric-friendly flu vaccines, expanding use of quadrivalent live attenuated vaccines, increasing seasonal flu prevention campaigns, development of multi-dose and single-dose nasal formulations.

The rising prevalence of influenza is expected to drive growth in the nasal spray influenza vaccine market. Influenza is a highly contagious viral infection that primarily affects the respiratory system, causing fever, cough, sore throat, body aches, and fatigue. Its prevalence is increasing due to frequent genetic mutations of the virus, which allow it to evade existing immunity and spread rapidly. Nasal spray influenza vaccines protect by delivering a weakened form of the virus directly into the nasal passages, stimulating an immune response at the site of infection. For instance, in September 2024, according to the Centers for Disease Control and Prevention (CDC), preliminary estimates for the 2023-2024 U.S. influenza season indicated 34-75 million symptomatic illnesses, 15-33 million medical visits, 380,000-900,000 hospitalizations, and 17,000-100,000 deaths, with older adults (≥65 years) accounting for 51% of hospitalizations and 68% of deaths. Therefore, the rising prevalence of influenza is fueling the growth of the nasal spray influenza vaccine market.

Major companies in the nasal spray influenza vaccine market are focusing on innovative formulations such as live attenuated influenza vaccines (LAIVs) to enhance immune response and improve patient compliance. LAIVs use live, weakened influenza viruses to stimulate antibody production and provide both local and systemic immunity without causing the disease, strengthening protection against future flu infections. For instance, in September 2024, AstraZeneca Plc, a UK-based pharmaceutical company, received U.S. FDA approval for FluMist, a LAIV that can be self-administered by adults up to 49 years or administered by caregivers to children aged 2-17 years. This approval marked FluMist as the first influenza vaccine in the U.S. approved for self- or caregiver-administration, based on usability studies showing 100% of participants delivered a full dose correctly.

In October 2023, Mylab Discovery Solutions Private Limited, an India-based biotechnology company, partnered with Serum Institute of India Private Limited to launch Nasovac S4, India’s first nasal influenza vaccine. This partnership aims to provide broad protection against multiple influenza strains through a needle-free nasal vaccine. Serum Institute of India specializes in Nasovac-S and Nasovac-S4, expanding access to innovative influenza prevention in the Indian market.

Major companies operating in the nasal spray influenza vaccine market are Sanofi Pasteur SA, GSK plc, FluGen Inc., BioDiem Ltd, Codagenix Inc, Altimmune Inc, AstraZeneca PLC, MedImmune LLC, BCHT Biotechnology Co Ltd, Serum Institute of India Pvt Ltd, Vivaldi Biosciences, Vaccitech, Blue Water Vaccines, VaxInnate, INOVIO Pharmaceuticals, Cipla Ltd, Beijing Wantai Biological Pharmacy Enterprise Co Ltd, Bharat Biotech, Novavax Inc, BioNTech SE, Transgene SA, BiondVax Pharmaceuticals Ltd, Adimmune Corporation, Teva Pharmaceutical Industries Ltd.

North America was the largest region in the nasal spray influenza vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasal spray influenza vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nasal spray influenza vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the nasal spray influenza vaccine market by increasing the cost of imported vaccine components, cold-chain packaging, and manufacturing inputs. Pediatric and adult vaccine segments in North America and Europe are particularly affected due to dependence on global vaccine supply chains. These trade barriers have raised distribution costs and affected pricing in some regions. However, tariffs are encouraging domestic vaccine production and local fill-and-finish operations.

The nasal spray influenza vaccine market research report is one of a series of new reports that provides nasal spray influenza vaccine market statistics, including nasal spray influenza vaccine industry global market size, regional shares, competitors with a nasal spray influenza vaccine market share, detailed nasal spray influenza vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the nasal spray influenza vaccine industry. This nasal spray influenza vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nasal spray influenza vaccine is a needle-free flu vaccine administered through the nose that uses live attenuated viruses to protect against seasonal influenza. It is delivered by spraying into the nostrils, where it stimulates an immune response in the nasal passages to provide protection against the flu.

The main types of nasal spray influenza vaccines include the live attenuated influenza vaccine (LAIV) and the inactivated influenza vaccine. The LAIV uses weakened live viruses to elicit strong systemic and mucosal immune responses. These vaccines are available in single-dose and multi-dose formats and are designed for different age groups, including pediatric, adult, and geriatric populations. Distribution channels include hospitals, clinics, pharmacies, online stores, and other outlets, with end users such as healthcare providers, individuals, government health departments, and pharmaceutical companies.

The nasal spray influenza vaccine market consists of sales of flumist quadrivalent, fluenz tetra, vaxinate, centripetal flu nasal spray vaccine, nasovac-s, fluvac nasal spray, and live attenuated influenza vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.